RET-IN-29
RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. RET-IN-29 exhibits inhibitory potency against the BaF3 cells harboring CCDC6-RETV804M mutation with an IC50 value of 0.715 μM. RET-IN-29 is promising for research of non-small cell lung cancer (NSCLC) [1].
Product Specifications
UNSPSC
12352005
Target
RET
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
CC1=C(N2C=CC(NC3=NC(N(C4CCC4)C(C=C5C)=O)=C5C=N3)=N2)C=CC=C1
Molecular Formula
C22H22N6O
Molecular Weight
386.45
References & Citations
[1]Shen J, et al. Structure-Based Design of 2-Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection (RET) Kinase Inhibitors. Chem Biol Drug Des. 2025 Jan;105 (1) :e70039.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
